Nanox will present its FDA‑cleared Nanox.ARC X multi‑source digital tomosynthesis system at the RSNA 2025 Annual Meeting in Chicago, the first public demonstration of a product that received 510(k) clearance in April 2025 for musculoskeletal, pulmonary, intra‑abdominal and paranasal indications.
The Nanox.ARC X delivers 3‑D imaging with a cold‑cathode X‑ray source that is smaller, more energy‑efficient and capable of lower radiation doses than conventional CT. The system’s rapid, 30‑minute setup and low‑dose output make it a practical alternative for routine clinical settings that previously relied on 2‑D X‑rays or expensive CT scanners.
In addition to the hardware, Nanox will launch three AI solutions: a pulmonary nodule detection model still in development, a standalone aortic valve calcification measurement tool, and a body‑composition analysis application. These tools are designed to extend the diagnostic reach of the ARC X and to streamline workflow for radiology practices, reinforcing Nanox’s strategy of combining hardware, cloud‑based teleradiology and AI.
Financially, Nanox has shown modest revenue growth in the last two quarters. Q3 2024 revenue rose to $3.0 million from $2.5 million in Q3 2023, while Q2 2025 revenue matched Q2 2024’s $3.0 million after a $0.3 million increase from $2.7 million. The company continues to post net losses—$13.6 million in Q3 2024 versus $21.4 million in Q3 2023—largely driven by ongoing R&D and marketing spend to support the new product launch. Cash and equivalents fell to $62.6 million at June 30, 2025 from $83.5 million a year earlier, reflecting the company’s high burn rate as it scales its technology and market reach.
CEO Erez Meltzer said the ARC X “bridges the gap between conventional X‑rays and CT scans, bringing advanced 3‑D imaging to everyday care settings where it hasn’t been practical before.” He added that the AI tools will help clinicians detect disease earlier and reduce the need for additional imaging, positioning Nanox as a comprehensive imaging‑solutions provider rather than a pure hardware vendor.
The RSNA showcase is a key milestone for Nanox, offering a platform to demonstrate the system’s clinical value to a large audience of radiology professionals. The company’s competitive advantage lies in its proprietary cold‑cathode technology, pay‑per‑scan business model and integrated cloud platform. Headwinds include the need for continued investment in AI development and the challenge of scaling production to meet demand, while tailwinds come from growing demand for low‑dose, high‑value imaging in underserved markets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.